drugset / Trial / NCT05932732
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
Phase 4
Completed
27 enrolled
Austin Institute for Clinical Research
The HydraFacial Company · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before and after three (3) HF treatments, in 6 patient cohorts, each cohort defined by FST I-VI.
Timeline
- Start
- 2023-11-20
- Primary completion
- 2024-10-09
- Completion
- 2024-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ReGen-GF | Unknown | — | — |